Compare QUBT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | VCEL |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | United States |
| Employees | 77 | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2019 | 1996 |
| Metric | QUBT | VCEL |
|---|---|---|
| Price | $8.13 | $33.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $17.50 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 12.9M | 533.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | $682,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $3,210.56 | $19.40 |
| Revenue Next Year | $51.26 | $18.24 |
| P/E Ratio | ★ N/A | $112.05 |
| Revenue Growth | ★ 82.84 | 16.45 |
| 52 Week Low | $6.18 | $28.95 |
| 52 Week High | $25.84 | $45.97 |
| Indicator | QUBT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 46.65 |
| Support Level | $7.70 | $31.24 |
| Resistance Level | $9.15 | $34.77 |
| Average True Range (ATR) | 0.68 | 1.52 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 40.71 | 10.17 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.